Acorda Therapeutics (ACOR) Receives Analyst Rating

Acorda Therapeutics (ACOR) : 4 analysts are covering Acorda Therapeutics (ACOR) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Acorda Therapeutics (ACOR) : Currently there are 3 street experts covering Acorda Therapeutics (ACOR) stock. The most bullish and bearish price target for the stock is $60 and $25 respectively for the short term. The average price target of all the analysts comes to $42.67. The estimated standard deviation from the target is $17.5.


Acorda Therapeutics (NASDAQ:ACOR): After opening at $25.03, the stock dipped to an intraday low of $24.73 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $25.912 and the buying power remained strong till the end. The stock closed at $25.71 for the day, a gain of 2.59% for the day session. The total traded volume was 467,752. The stocks close on the previous trading day was $25.06.

Acorda Therapeutics, Inc. is a biopharmaceutical company engaged in the identification, development and commercialization of therapies that restore neurological function and treat patients with neurological disorders. The Companys markets three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10milligrams, a treatment to improve walking in patients with multiple sclerosis (MS). It also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company is also developing a number of clinical and preclinical stage therapies for the treatment of a range of disorders, including chronic post-stroke walking deficits (PSWD), Parkinsons disease, epilepsy, heart failure, MS, and spinal cord injury.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *